Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.34 |
| ▸ | RARB | P10826 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310394 | 0.93 | FFAR1 (0.37) | FFAR1FFAR4S1PR1S1PR3RARB | |
| SCHEMBL18310447 | 0.88 | RARB (0.32) | FFAR1FFAR4RARBRARA | |
| SCHEMBL18310522 | 0.87 | RARB (0.31) | FFAR1FFAR4RARBRARA | |
| SCHEMBL18310454 | 0.85 | FFAR1 (0.34) | FFAR1FFAR4S1PR1S1PR3RARB | |
| SCHEMBL18540240 | 0.84 | FFAR1 (0.48) | FFAR1FFAR4S1PR1S1PR3PTGES | |
| SCHEMBL15180192 | 0.83 | RARB (0.40) | S1PR1S1PR3RARBRARAMAOB | |
| SCHEMBL16258133 | 0.83 | FFAR4 (0.39) | FFAR1FFAR4S1PR1RARBRARA | |
| SCHEMBL18458484 | 0.83 | GPR52 (0.40) | FFAR1RARBRARA | |
| SCHEMBL11957385 | 0.83 | FFAR4 (0.39) | FFAR1FFAR4S1PR1RARBRARA | |
| SCHEMBL20849604 | 0.83 | GPR52 (0.40) | FFAR1RARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951277-B2 | Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | FFAR1 492/4885FFAR4 1281/4885S1PR1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.